Alkermes PLC
(NAS:ALKS)
$
27.84
0.09 (0.32%)
Market Cap: 4.58 Bil
Enterprise Value: 4.06 Bil
PE Ratio: 16.57
PB Ratio: 3.60
GF Score: 67/100 Alkermes Plc at UBS Global Healthcare Conference Transcript
May 20, 2019 / 12:00PM GMT
Release Date Price:
$22.81
(-1.25%)
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Good morning, and welcome to day 1 of the UBS Global Healthcare Conference. My name is Navin Jacob. I'm the senior analyst covering large-cap pharmaceuticals and SMID-cap biotech. For the first session this morning, we will have a fireside chat with the management team from Alkermes Pharmaceuticals. I'm happy to have with me Blair Jackson, SVP of Corporate Planning. Blair, thank you for joining us today.
Blair C. Jackson
Alkermes plc - SVP of Corporate Planning
Thanks for having us.
Questions & Answers
Navin Cyriac Jacob;Blair C. Jackson
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic;Alkermes plc - SVP of
Maybe we could start with a discussion of ARISTADA. What are the growth opportunities ahead for the remainder of 2019 that would make your guidance achievable?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot